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Background: Hematopoiesis is a complex process that encompasses both pro-mitotic
and anti-mitotic stimuli. Pharmacological agents used in chemotherapy have a prominent
anti-mitotic effect. The approach of inhibiting cell proliferation is rational with respect to
the rapidly dividing malignant cells. However, it poses a serious problem with respect to
cell proliferation of cell types required for the ‘house-keeping’ operations of the human
body. One such affected system is hematopoiesis. Chemotherapy induced anemia is an
undesired side effect of chemotherapy that can lead to serious complications. Patients
exhibiting anemia or leukopenia during chemotherapy are frequently administered a
hematopoietic inducing agent that enhances hematopoiesis.
Methods: In previous work, we derived a mathematical model consisting of a set of delay
differential equations that was dependent on the effect of a hematopoietic inducing
agent. The aim of the current work was to formulate a mathematical model that captures
both the effect of a chemotherapeutic agent in combination with a hematopoietic
inducing agent. Steady state solutions and stability analysis of the system of equations
is performed and numerical simulations of the stem cell population are provided.
Results: Numerical simulations confirm that our mathematical model captures the
desired result which is that the use of hematopoietic agents in conjunction with
chemotherapeutic agents can decrease the negative secondary effects often
experienced by patients.
Conclusions: The proposed model indicates that the introduction of hematopoietic
inducing agents have clinical potential to offset the deleterious effects of chemotherapy
treatment. Furthermore, the proposed model is relevant in that it enhances the
understanding of stem cell dynamics and provides insight on the stem cell kinetics.
Keywords: Hematopoiesis, Chemotherapy, Linear Stability AnalysisIntroduction
The process by which Hematopoietic Stem Cells (HSC) residing in the bone marrow
differentiate into blood cells is known as hematopoiesis. HSCs can be classified as
either non-proliferating or proliferating. In a healthy person, HSC constantly divide
and differentiate into blood cells by going through different phases of the cell cycle
(see Figure 1A). Stem cells involved in hematopoiesis initially begin as undifferentiated© 2014 Mouser et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Figure 1 HSC cycle and cell count A. (Left) In the absence of a CTA, Non-proliferating cells which are in
the dormant phase (G0) are constantly signaled by microenvironmental cues to enter into the cycling state.
Once signaled, the cells undergo mitosis. Cells exposed to an exogenous HIA are further induced to enter
the (G1) phase, and undergo synthesis of DNA (S). The cells then enter the next phase (G2) where additional
proteins involved in cell cycling are produced to allow for cell division to occur. Once the cells complete
mitosis (M), they renter the resting phase. During this cycle, some cells propagate to differentiation paths
(at a rate) into the various hematopoietic lines or lost by apoptosis (at a rate). However, in the presence of
a strong CTA, the synthetic phase (S) is blocked, leading to apoptosis and loss of both differentiated and
undifferentiated stem cells. (Right) HSC residing in the main sinus of the bone marrow (BM), divide into two
new cells during the process of mitosis. During chemotherapy cell divisions are seriously compromised.
B. Absolute CD34+ progenitor quantification in patient cohort receiving G-CSF (Neupogen). A total of 92
patients were assayed using flow cytometry and the ISHAGE protocol. Stem cell phenotype was confirmed
through simultaneous detection of the CD34, CD38, and CD45 markers.
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ision of stem cells. In cases of high intensity chemotherapy stem cell rescue is applied
[1]. The undesired effect of CTAs leads to serious complications in cancer patients
receiving chemotherapy. To overcome this issue, a Hematopoietic Inducing Agent
(HIA) is often employed. The effect of the HIA is pro-mitotic and essentially offsets the
excessive anti-mitotic impact of CTA.
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(EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) play a vital role in
hematopoiesis and are capable of inducing proliferation of stem cells [2,3]. Understanding
the role of HIA during chemotherapy is critical in developing optimal chemotherapeutic
treatments. For patients undergoing chemotherapy, it is necessary to increase or stabilize
the production of red blood cells and concurrent administration of HIA with CTA can
potentially decrease the secondary effects of CTA. During CTA treatment, cancer patients
frequently experience a significant reduction in red blood cells (anemia), leukocytes
(leucopenia), neutrophils (neutropenia) and platelets (thrombocytopenia) typically treated
with recombinant Erythropoietin (EPO), Granulocyte-Colony Stimulating Factor (G-CSF)
and corticosteroids respectively. Thus, use of HIA in conjunction with CTA can aid in
stabilization of red blood cell levels and leukocyte number expansion [4,5].
Mathematical models can be used to gain insight into the underlying mechanisms
that control stem cell production under normal conditions and during tumor growth
[6-8]. In previous work, we constructed a mathematical model that described the be-
havior of both proliferating (P) and non-proliferating (N) HSCs as they go through the
cell cycle [9]. This model was novel in the sense that it incorporated the effect of HIA
on the cells. Simulations of our model closely matched experimental results in which
92 patients were administered G-CSF (Neupogen). These patients were assayed using
flow cytometry and the ISHAGE protocol and showed increased CD34+ stem cell
levels, as was expected [9]. We have used the same clinical sample to calibrate the new
model in terms of the number of stem cells seen in a typical patient. The chosen range
of 50–150 stem cells is the number of CD34+ cells per 10,000 peripheral blood leuko-
cytes analyzed and is an indirect measure of HSCs; see Figure 1B. Similar measure-
ments were reported by Kato and Radbruch [10].
The aim of the current work is two-fold. We first revisited our model [9] of P and N
where the role of HIA was incorporated with the goal of modeling the effect of HIA in
a time-dependent manner. This made the model more physiologically relevant. In the
previous model, HIA was described by a Hill function such that when the level of
proliferating cells was low, HIA was triggered to stimulate the non-proliferating cells to
become proliferating. Once the level of proliferating cells was above a certain threshold,
the proliferation of HSC was signaled to stop. Hill functions are commonly used when
describing a phenomenon that is saturable and nonlinear, and are very effective in
fitting experimental data. They have been used extensively to describe the relationship
between the dosage of a drug and its effect. However, one drawback of this class of
functions is that they may not capture the true biological mechanism at play [11]. The
equations in our previous model assumed no time dependence for this process. In a
biologically realistic setting, however, the effect of HIA on HSC decays with time [12].
This is primarily due to the degradation of the HIA with respect to time. We therefore
incorporated this time dependence into our model by revising the mathematical term
that describes the effect of HIA in our system of equations (see equation (4); Figure 2).
The second goal of this work was to incorporate the effect of a chemotherapy agent
(CTA) into the model. Since cancer patients experience reduced leukocyte levels and
anemia during chemotherapy treatment, simultaneous administration of HIA can
stabilize their red blood and white cell count [13,14]. The overall goal of our study was
to determine the dynamic interaction between CTAs and HIAs during chemotherapy.
Figure 2 Effect of time-dependence on proliferating cells. Top curve shows P versus t when the effect
of HIA is not time dependent. Bottom curve shows P versus t when the effect of HIA is time dependent.
The time dependency causes the solution trajectory to reach a lower steady state value than it would
without the time dependency. In both cases, chemotherapy treatment is absent.
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treatment with respect to time. Our mathematical model incorporates both time
dependence and chemotherapy effect, and provides numerical simulations of the stem
cell population with respect to time.
Materials and methods
The model
We expanded upon the model that we previously constructed and published [6]. This
model describes the number of proliferating and non-proliferating stem cells in
response to HIA by a set of coupled delay differential equations. Our new model
accounts for HIA but in a time dependent manner. In addition, the new model
accounts for the effect of CTA on the proliferation of HSCs. As opposed to our previ-
ous work, we have assumed a fixed oxygen concentration in the model. The modeling
set of equations is:
dP=dt ¼ −γP þ β Nð ÞN− exp −γτð Þβ Nτð ÞNτ þ βHIA Pð ÞN−βC Pð ÞN ; τ < t ð1Þ
dN=dt ¼ − β Nð ÞN þ δN½  þ 2 exp −γτð Þβ Nτð ÞNτ−βHIA Pð ÞN þ βC Pð ÞN ; τ < t ð2Þ
β Nð Þ ¼ β0
θn
θn þ Nn ð3Þ
βHIA Pð Þ ¼ β0;HIA
θm1
θm1 þ Pm
gHIA tð Þ ð4Þ
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1 ; 0 < t≤τ1
exp −s1 t−τ1ð Þð Þ ; t > τ1

and
βC Pð Þ ¼ β0;C
Pw
θw2 þ Pw
gC tð Þ ð5Þ
gc tð Þ ¼
1 ; 0 < t≤τ2
exp −s2 t−τ2ð Þð Þ ; τ2 < t≤τ3
exp −s2 τ3−τ2ð Þð Þ ; t > τ3
8<
:
In the above equations, P represents the number of proliferating stem cells and N
represents the number of non-proliferating cells. β(N) (equation (3)) measures the rate
of cell re-entry into proliferation, β0 is the maximal rate of cell transit from resting
phase to S phase, n measures the sensitivity of the rate of cell transit from G0 phase to
S phase, and θ is the G0 stem cell population at which the rate of cell movement from
G0 into proliferation is one-half of its maximal value. δ is the rate of random cell loss
by escape to the periphery and γ is the rate of cell loss due to apoptosis. τ is the time
required for a cell to complete one cycle of the proliferation phase. The notation N ,
for example, represents N(t − τ) thus introducing a time delay into the equations. The
values of parameters stated above are based on estimates given by Mackey [15,16].
The term βHIA(P)N in equations (1) and (2) models the effect of HIA on the proliferat-
ing and non-proliferating stem cells and is a Hill function. This term models the effect of
HIA by creating a cell loss of the non-proliferating population and a cell gain of the prolif-
erating population when the proliferating cell population is low. This represents the tran-
sition of non-proliferating to proliferating cells as a result of HIA administration. As
stated above, in our previous work, this term did not display any time dependence. To in-
corporate the time dependence of HIA, we therefore modified βHIA (equation (4)) so that
its effect decays with time as it occurs in a biological system. This effect is captured by the
function gHIA(t) . The parameter s1 determines the rate of decay and τ1 is a parameter that
sets the time at which the effect of HIA begins to decay. The last term in equations (1)
and (2) models the effect of CTA treatment on the level of proliferating and non-
proliferating stem cells. CTA administration in patients causes a decrease in the number
of proliferating stem cells. We aimed to model this effect by constructing βC(P) (equation
(5)) to be a Hill function that ranges from a minimum value of 0 to a maximum value of
β0, C. θ2 is the half activation value of the cells in response to CTA and w determines the
sensitivity of the rate at which cells proliferate due to changes in CTA concentration.
Thus when the proliferating cells are at a high level, the CTA term causes a decrease in
the proliferating cell count (caused by a transition of proliferating cells into the non-
proliferating cell population). Once the population of proliferating cells has decreased be-
yond the threshold point θ2, the effect of CTA is removed. This term captures the time
dependent impact of chemotherapy treatment through the function gC(t) where the pa-
rameters s2, τ2, and τ3, behave in a similar manner to the time decay of HIA. The param-
eter values in the term βHIA(P) and βC(P) were chosen to be consistent with realistic time
frames of HIA and chemotherapy effects as noted in [17-19]. Parameter values used in
our model are given in Table 1 (unless otherwise stated). Note that in the presence of
chemotherapy treatment, the initial number of proliferating stem cells was increased from
Table 1 Parameter values used in simulations of model
In absence of CTA In presence of CTA
P0 50 cells/10,000 peripheral blood leukocytes 100 cells/10,000 peripheral blood leukocytes
N0 70 cells/10,000 peripheral blood leukocytes 70 cells/10,000 peripheral blood leukocytes
δ 0.09/days 0.09/days
γ 0.15/days 0.15/days
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leukocytes because patients undergoing chemotherapy treatment typically display
an increased number of proliferating cells [20].
Steady-state solutions of the model and stability analysis
Steady-state solutions for the proliferating and non-proliferating cells have been calcu-
lated and linear stability analysis of equations (1) and (2) has been carried out as in
[9,21,22]. Two sets of steady-state solutions were found. The first set is P* =N* = 0. The
second and more interesting steady-state solution is:














The nontrivial steady state exists only if
0 < γτ < ln
2β0
δ þ β0;HIA−β0;C þ β0
: ð8Þ









A¼ δ þ β0F þ β0;HIA
B ¼ −2β0e−γτF−βc and
F ¼ θn θ
n þ 1−nð Þ Nð Þn
θn þ Nð Þn½ 2
With the restriction that AB
  < 1:
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the system to remain active. The condition in equation (8) reflects the fact that if
apoptosis exceeds certain values, hematopoiesis will cease leading to death. Note that
if β0,C = 0, γτ lies in a smaller range than if β0,C > 0 for the nontrivial steady state to
exist. This allows flexibility for γ to be larger in the presence of CTA treatment.
Furthermore, for homeostasis to prevail, the collection of parameter values must yield
dynamic equilibrium (as given by equations (6) and (7)).
Results
The analysis of our modeling set of equations shows that under the combination of
HIA and CTA treatment the number of proliferating and non-proliferating cells can
reach a stable, steady state under various conditions. To confirm these results, simula-
tions of our model were run using the mathematical software XPPAUT which is a dif-
ferential equation solving package that has an interface to AUTO (a bifurcation
construction program) [23]. We considered several cases when running numerical sim-
ulations in order to better understand the effects of HIA treatment and CTA treatment.
We considered the effect of HIA when administered in the absence of CTA, the effect
of CTA when administered in the absence of HIA, and the effect of HIA and CTA
when administered jointly. We also ran simulations to determine the effect of the time
dependency of the decay of HIA. In all simulations, the units of proliferating and non-
proliferating cell counts are in cells per 10,000 peripheral blood leukocytes. Simulations
were run for several parameter values. However, all figures presented are based on only
one simulated set of parameter values.
As stated earlier, the time dependence of HIA was incorporated into the current
model to reflect that its effects decay with time. Figure 2 shows the solution trajectory
for the proliferating cells in the presence of HIA (chemotherapy treatment is absent)
when HIA is time dependent versus when it is not time dependent. This figure shows
that in the time dependent case, the effect of HIA wears off and therefore causes the
level of proliferating cells to reach a lower steady state value than when the time
dependence is excluded from the modeling set of equations. This time dependence is
more comparable to what happens in vivo.
Solution trajectories under various combinations of the presence and absence of HIA
and CTA treatment are shown in Figures 3, 4, 5, and 6 for different parameter sets. In
the control case (Figure 3A) which measures the number of proliferating and non-
proliferating HSC in the absence of HIA and CTA treatment, simulations of the model
were run with P(0) = 50 and N(0) = 70. The solution trajectories show that initially the
number of HSC oscillates but then reaches a steady state value of approximately 45
proliferating cells and 115 non-proliferating cells. In the subsequent case (Figure 3B),
we allowed the solution trajectories to reach their steady state values in the control case
and then added HIA to the model. In this case, the effect of HIA causes an increase in
the number of proliferating cells. Once the effect of HIA wears off due to the time de-
pendency in the model, the solution trajectory decreases and reaches the same steady
state as in the control case. In Figure 3C, we consider the effect of CTA treatment in
the absence of HIA. We increased the initial level of proliferating cells to P(0) = 100
and changed β0 and n in our model so that the steady state value of the proliferating
cells without CTA or HIA treatment is 100. This accounts for the fact that patients
Figure 3 Numerical simulations of proliferating and non-proliferating cells in the absence and presence
of HIA and CTA treatment. Simulations of the model show P versus t (bottom curve) and N versus t
(top curve). A. HIA and chemotherapy treatment are both absent (the control case). B. HIA is present and
chemotherapy treatment in absent. It can be observed that HIA causes an increase in the level of P as
compared with the control case. Due to the time dependent nature of HIA, the steady state value of P is
the same as in the control case. C. HIA is absent and chemotherapy treatment is present. The presence of
CTA causes a drastic decrease in the level of P as compared with the control case. The steady state value of
P is below the initial value P(0) = 100 which is the desired result. D. HIA and chemotherapy treatment are
both present. For an appropriate choice of the dosage of HIA administration, the minimum level of P can
be kept close to that observed in the control case.
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cells as seen in the study used in our previous work [9]. We again allowed the solution
trajectories to reach their steady values and then added in CTA. In this case, the solu-
tion trajectory for the proliferating cells significantly decays as is to be expected since
CTA treatment is administered to patients in order to kill cancer cells. However, once
the effect of CTA treatment wears off due to the time dependent nature of the model,
the solution trajectory approaches approximately 80 cells. This models the effect of one
application of CTA treatment [24]. Subsequent applications of CTA treatment would
aim to bring the steady state value of the proliferating cells to that of the control case.
Finally in Figure 3D, solution trajectories of the model are shown in the presence of
HIA and CTA treatment. In this simulation, the initial level of proliferating cells is
again set to P(0) = 100 and the same parameter values of the model are used as in
Figure 3C with the addition of HIA. In this case, HIA administration increases the
mean number of proliferating cells as compared with the mean number when CTA
treatment alone is administered. Based on the study presented by Benboukher et al.
[25], administration of G-CSF/GM-CSF in chemotherapy treated patients significantly
increased the number of CD34+ cells. Thus, our model captures the effect of HIA
which in conjunction with CTA treatment can prevent abnormally low levels of stem
Figure 4 Numerical simulations of proliferating and non-proliferating cells in the absence and presence
of HIA and CTA treatment under different parameter settings. Simulations of the model show P versus
t (bottom curve) and N versus t (top curve) in four cases. A. HIA and chemotherapy treatment are both
absent (the control case). B. HIA is present and chemotherapy treatment in absent. C. HIA is absent and
chemotherapy treatment is present. D. HIA and chemotherapy treatment are both present. In all four
simulations m was increased from 0.1 to 1, θ1 was decreased from 100 to 60, w was increased from 1 to 2,
and θ2 was decreased from 100 to 60. The increase in w reflects an increase in the sensitivity of the rate at
which cells proliferate due to changes in CTA treatment. The increase in θ1 reflects a decrease in the
sensitivity of the rate at which cells proliferate due to changes in HIA administration. The decrease in θ1
and θ2 from 100 to 60 causes a response in stem cells due to CTA and HIA at lower levels of the HSC
population. These changes in parameter values do not significantly alter the overall HSC levels as compared
with Figure 3. Note that there is no change from Figure 3A to Figure 4A since in this case, HIA
administration and CTA treatment are absent.
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the proliferating cells returns to the same value as when the CTA alone is present.
In Figure 4, simulations were run for the four cases (absence of HIA and CTA, pres-
ence of HIA, presence of CTA, and presence of both HIA and CTA) but m was
increased from 0.1 to 1, θ1 was decreased from 100 to 60, w was increased from 1 to 2,
and θ2 was decreased from 100 to 60. Recall that m and w determine the sensitivity of
the rate at which cells proliferate due to changes in HIA administration and CTA treat-
ment, respectively. The increase in m reflects a decrease in the sensitivity (decrease in
the slope of the Hill function βHIA(P)) due to HIA administration. The increase in w
reflects an increase in the sensitivity (increase in the slope of the Hill function βC(P))
due to CTA treatment. θ1 and θ2 are the half-activation values of the cells in response
to HIA and CTA, respectively. Therefore, the decrease in these values from 100 to 60
causes a response in stem cells due to HIA and CTA at lower levels of the HSC popula-
tion. In order for the HIA administration to be effective at preventing the severe drop
in HSC levels during CTA treatment, the values of θ1 and θ2 must be kept close to one
Figure 5 Numerical simulations of proliferating and non-proliferating cells in the absence and presence
of HIA and CTA treatment with a slower decay rate of HIA and CTA effects. Simulations of the model
show P versus t (bottom curve) and N versus t (top curve) in four cases. A. HIA and chemotherapy
treatment are both absent (the control case). B. HIA is present and chemotherapy treatment in absent.
C. HIA is absent and chemotherapy treatment is present. D. HIA and chemotherapy treatment are both
present. In these simulations, the values of s1 and s2 were decreased from 0.2 to 0.1 (with all other
parameter values as in Table 1). This causes the effect of HIA administration and CTA treatment on HSC
levels to wear off more slowly as can be seen in comparison with Figure 3. Note that there is no change
from Figure 3A to Figure 5A since in this case, HIA administration and CTA treatment are absent.
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values do not significantly alter the overall HSC levels as compared with Figure 3.
In order to determine the effect of changing the decay rate of the HIA and CTA
terms in equations (1) and (2), the values of s1 and s2 were decreased from 0.2 to 0.1.
Thus, the effect of HIA administration and CTA treatment wears off more slowly. The
simulation results corresponding to these values of s1 and s2 (with all other parameter
values as in Table 1) are presented in Figure 5 and show a slower decay of both CTA
and HIA effects compared with Figure 3. However, the overall behavior of the HSC
levels is consistent with that of Figure 3.
Figure 6A shows the solutions trajectories of the proliferating cells plotted against
one another in 2 cases; a heightened steady state value of the proliferating cells with
CTA present and HIA absent and CTA present with HIA. This figure allows us to see
more clearly the effects of HIA and CTA. In trace 1, we see that CTA treatment alone
causes a drastic decrease in the number of proliferating stem cells approximately 5 days
after CTA is administered. In the absence of HIA and presence of CTA, the minimum
value of the number of proliferating cells is approximately 17 and this is attained when
the effect of CTA treatment is at its maximum. When HIA is added (trace 2), the mini-
mum value of the number of proliferating cells is approximately 45. This is a rational
result since patients undergoing CTA treatment often become anemic and EPO can
Figure 6 Comparisons of proliferating cell counts in the absence and presence of HIA and CTA
treatment. Solution trajectories for P are plotted against one another in various cases in order to
determine the effect that HIA and CTA have on the number of proliferating stem cells. A. Trace 1 shows the
solution trajectory for the heightened steady state in the presence of CTA and absence of HIA. Trace 2
shows the solution trajectory in the presence of both CTA and HIA. It can be seen that CTA treatment
alone causes a decrease in the equilibrium value of P compared to when CTA treatment is absent. The
addition of HIA with CTA prevents the solution trajectory from reaching the extreme minimum that is
reached when CTA treatment is administered alone. B. Solution trajectories for high (trace 1, β0,C = 0.301),
medium (trace 2, β0,C = 0.206), and low (trace 3, β0,C = 0.048) doses of CTA treatment in the absence of HIA
are plotted. As the dosage increases, the steady state value of the proliferating cells decreases. C. Simulations of
P are shown with CTA treatment alone (trace 1) and at low (trace 2), moderate (trace 3) and high (trace 4)
dosages of HIA administration in conjunction with CTA treatment. At a moderate dosage, the minimum value
of P is close to the steady state value of the control case.
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(trace 1), medium (trace 2), and low (trace 3) doses of CTA treatment without HIA
administration. As is to be expected, the steady state value of the proliferating cells
decreases as the dosage increases. However, if the dosage is too high, the number of
proliferating cells approaches 0 within days of administration. In Figure 6C, simula-
tions of the model were run during CTA treatment without HIA administration
(trace 1) and at low (trace 2), moderate (trace 3), and high (trace 4) doses of HIA
administration during CTA treatment. This result shows that when the dosage of
HIA is too low, it is not effective at bringing the minimum value of the proliferating
cells (occurring at approximately day 5) back to that of the normal levels (shown by
the straight line). On the other hand, when the dosage is too high, the number of
proliferating cells overshoots that of the steady state in the control case. Thus, the
appropriate choice for this dosage (as controlled by β0,HIA) is necessary to produce
the desired outcome. All of the results are in agreement with the stability analysis
performed above.
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The use of potent anti-mitotic drug(s) to reduce proliferation of malignant cells is a
widely used tool in oncology. Unfortunately, it is associated with serious side effects
that manifest themselves in a variety of forms such as anemia and leukopenia [26,27].
The model presented in this study demonstrates the expected outcome of chemother-
apy treatment. A drastic reduction in the number of proliferating stem cells occurs
which with respect to time recovers to a steady state value below the normal number
of proliferating stem cells. This phenomenon is not surprising and is thought to play a
pivotal role in terms of the toxicity associated with chemotherapy. In the case of con-
current chemotherapy treatment and hematopoietic inducing agent, the model demon-
strates two noteworthy phenomena. The first one is HIA administration increases the
nadir observed in the proliferative cell line compared with when CTA treatment alone
is administered. This is significant in preventing patients undergoing chemotherapy
treatment from experiencing secondary effects. Furthermore, the steady state value of
the proliferating cells is significantly lower after CTA treatment, thereby, bringing pa-
tients closer to the steady state of the control case.
It is important to note that this model provides a theoretical outcome. The simplify-
ing mathematical assumptions that were made allow for analysis of an otherwise overly
complex system for which the exact control mechanisms are not well understood. The
value of theoretical models lies in the relation of parameters that match individual
patients. The challenge is clinically determining these parameters before subjecting the
patient to chemotherapy. The cost to determine individualized parameters of each
patient before subjecting them to chemotherapy can be prohibitive. However, the
model is relevant in that it enhances the current understanding of stem cell dynamics
and provides insight on the stem cell kinetics with respect to time. This can help clinicians
refine standard treatments.
The model and accompanying analysis bring forth an interesting question that has
ramifications in the field of oncology: Is concurrent administration of a HIA during
chemotherapy a prudent approach for reducing toxicity during chemotherapy? There is
substantial clinical evidence to suggest that HIAs are useful in cases of anemia. Prophy-
lactic use of HIAs with chemotherapeutic agents at the onset of treatment seems
rational, at least on a theoretical level. However, one has to balance the cost of these
treatments with respect to clinical benefit. Equally relevant is the risk of inducing
adverse side effects through the use of HIAs such as venous thromboembolism and
tumor progression [28,29]. In future work, we will attempt to capture the pharmaco-
kinetic pattern and fluctuations of different drug effects with respect to proliferating
stem cells.
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